REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63.
2. Wu EM, Wong LL, Hernandez BY, et al. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res 2018;4:66.
3. Liu Y, Zheng J, Hao J, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med 2022;11:1310-23.
4. Huang DQ, Hoang JK, Kamal R, et al. Antiviral therapy utilization and 10-year outcomes in resected hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma. J Clin Oncol 2024;42:790-9.
5. Tan DJH, Setiawan VW, Ng CH, et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology 2023;77:1150-63.
6. Pan C, Attar B, Lo C, Achebe I. S1531 epidemiological trends and gender differences in hepatocellular carcinoma: analysis from the global burden of disease study 2019. Am J Gastroenterol 2023;118:S1161. Available from: https://scholar.google.com/scholar?hl=zh-CN&as_sdt=0%2C5&q=10.14309%2F01.ajg.0000955764.74781.d8&oq=%3A10.14309%2F01.ajg.0000955764.74781.d8. [Last accessed on 3 Dec 2024].
7. Beudeker BJB, Guha R, Stoyanova K, et al. Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology. Sci Rep 2024;14:4302.
8. Liou WL, Tan TJ, Chen K, Goh GB, Chang JP, Tan CK. Gender survival differences in hepatocellular carcinoma: is it all due to adherence to surveillance? JGH Open 2023;7:377-86.
9. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-41.
10. Davis JL, Buchanan KL, Katz RV, Green BL. Gender differences in cancer screening beliefs, behaviors, and willingness to participate: implications for health promotion. Am J Mens Health 2012;6:211-7.
11. O'Brien R, Hunt K, Hart G. ‘It’s caveman stuff, but that is to a certain extent how guys still operate’: men’s accounts of masculinity and help seeking. Soc Sci Med 2005;61:503-16.
12. Pelletier R, Humphries KH, Shimony A, et al; GENESIS-PRAXY Investigators. Sex-related differences in access to care among patients with premature acute coronary syndrome. CMAJ 2014;186:497-504.
13. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020;396:565-82.
14. Farinati F, Sergio A, Giacomin A, et al; Italian Liver Cancer group. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009;21:1212-8.
15. Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 2007;13:4295-305.
16. Zhong GC, Liu Y, Chen N, et al. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies. Hum Reprod Update 2016;23:126-38.
17. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012;148:72-83.
18. Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014;59:1406-14.
19. Tanaka K, Sakai H, Hashizume M, et al. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000;60:5106-10.
21. Liang T, He Y, Mo S, et al. Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy. Ann Hepatol 2022;27:100695.
22. Lam CM, Yong JL, Chan AO, et al. Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related? J Clin Gastroenterol 2005;39:533-9.
23. Chow PK, Tai BC, Tan CK, et al; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002;36:1221-6.
24. Nevola R, Tortorella G, Rosato V, et al. Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma. Biology 2023;12:984.
25. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009;50:1392-402.
26. Cherubini A, Ostadreza M, Jamialahmadi O, et al; EPIDEMIC Study Investigators. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med 2023;29:2643-55.
27. Li A, Wang R, Zhao Y, Zhao P, Yang J. Crosstalk between epigenetics and metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease-induced hepatocellular carcinoma: a new sight. Metabolites 2024;14:325.
28. Rongrui L, Na H, Zongfang L, Fanpu J, Shiwen J. Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis. Curr Pharm Des 2014;20:1715-25.
29. Li CL, Li CY, Lin YY, et al. Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription after hepatitis B virus integration or point mutation in promoter region. Hepatology 2019;69:498-512.
30. Ji F, Zhang J, Liu N, et al. Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression. Gut 2022;71:2313-24.
31. Abboud Y, Ismail M, Khan H, et al. Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: a nationwide analysis of two decades. J Clin Transl Hepatol 2024;12:172-81.
32. White AM. Gender differences in the epidemiology of alcohol use and related harms in the United States. Alcohol Res 2020;40:01.
33. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019;70:1457-69.
34. Lonardo A, Ballestri S, Chow PKH, et al. Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms. Hepatoma Res 2020;6:83.
35. Piscaglia F, Svegliati-Baroni G, Barchetti A, et al; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827-38.
36. Ladenheim MR, Kim NG, Nguyen P, et al. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol 2016;3:e000107.
37. Rich NE, Murphy CC, Yopp AC, Tiro J, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;52:701-9.
38. Balcar L, Scheiner B, Fulgenzi CAM, et al. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma. JHEP Rep 2024;6:100982.
40. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;26:3860-6.
41. Kalff MC, Dijksterhuis WPM, Wagner AD, et al. Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: a population-based study. Eur J Cancer 2023;187:114-23.
42. Dijksterhuis WPM, Kalff MC, Wagner AD, et al. Gender differences in treatment allocation and survival of advanced gastroesophageal cancer: a population-based study. J Natl Cancer Inst 2021;113:1551-60.
43. Wu C, Chen P, Qian JJ, et al. Effect of marital status on the survival of patients with hepatocellular carcinoma treated with surgical resection: an analysis of 13,408 patients in the surveillance, epidemiology, and end results (SEER) database. Oncotarget 2016;7:79442-52.
44. Flores YN, Datta GD, Yang L, et al. Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study. Cancer Epidemiol Biomarkers Prev 2021;30:1193-9.
45. Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Med 2021;10:7347-59.
46. Jones PD, Scheinberg AR, Muenyi V, Gonzalez-Diaz J, Martin PM, Kobetz E. Socioeconomic and survival differences among minorities with hepatocellular carcinoma in Florida. J Hepatocell Carcinoma 2019;6:167-81.
47. Karnam RS, Chen S, Xu W, et al. Sex disparity in liver transplant and access to living donation. JAMA Surg 2021;156:1010-7.
48. Locke JE, Shelton BA, Olthoff KM, et al. Quantifying sex-based disparities in liver allocation. JAMA Surg 2020;155:e201129.
49. Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias. Am J Transplant 2007;7:685-92.
50. Allen AM, Heimbach JK, Larson JJ, et al. Reduced access to liver transplantation in women: role of height, MELD exception scores, and renal function underestimation. Transplantation 2018;102:1710-6.
51. Durand F. The quest for equity in liver transplantation: another lesson learned from women. J Hepatol 2011;54:401-2.
52. Nephew LD, Goldberg DS, Lewis JD, Abt P, Bryan M, Forde KA. Exception points and body size contribute to gender disparity in liver transplantation. Clin Gastroenterol Hepatol 2017;15:1286-93.e2.
53. Koh JH, Chee D, Ng CH, et al. Sex-based disparities in liver transplantation for hepatocellular carcinoma and the impact of the growing burden of NASH. Transplant Direct 2024;10:e1642.
54. Koh JH, Ng CH, Nah B, Tan DJH, Loomba R, Huang DQ; Nash HCC Transplant Collaborative. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2024;22:197-9.e3.
